Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.

Article  PubMed  PubMed Central  Google Scholar 

Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365–80.

PubMed  PubMed Central  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

Article  PubMed  CAS  Google Scholar 

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–31.

Article  PubMed  CAS  Google Scholar 

Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447–60.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

Article  PubMed  CAS  Google Scholar 

Tan PS, Haaland B, Montero AJ, Kyriakopoulos CE, Lopes G. Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison. Clin Med Insights Oncol. 2014;8:29–36.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16:e645–53.

Article  PubMed  Google Scholar 

Lee YHA, Zhou J, Hui JMH, Liu X, Lee TTL, Hui K, et al. Risk of new-onset prostate cancer for metformin versus sulfonylurea use in type 2 diabetes mellitus: a propensity score–matched study. J Natl Compr Cancer Netw. 2022;20:674–82.e15.

Article  CAS  Google Scholar 

Chan JSK, Satti DI, Lee YHA, Hui JMH, Lee TTL, Chou OHI, et al. High visit-to-visit cholesterol variability predicts heart failure and adverse cardiovascular events: a population-based cohort study. Eur J Prev Cardiol. 2022;29:e323–5.

Article  PubMed  Google Scholar 

Chan JSK, Lee YHA, Liu K, Hui JMH, Dee EC, Ng K, et al. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy. Eur J Clin Invest. 2023;53:e13932.

Article  PubMed  CAS  Google Scholar 

Lee YHA, Hui JMH, Chan JSK, Liu K, Dee EC, Ng K, et al. Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: a population-based study. Prostate. 2023;83:119–27.

Article  PubMed  CAS  Google Scholar 

Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21:241.

Article  PubMed  PubMed Central  Google Scholar 

McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9:403–25.

Article  PubMed  Google Scholar 

Sturmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275:570–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Health Patient Saf. 2015;7:129–38.

Google Scholar 

Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation. 1985;71:645–9.

Article  PubMed  CAS  Google Scholar 

Attard G, Merseburger AS, Arlt W, Sternberg CN, Feyerabend S, Berruti A, et al. Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study. JAMA Oncol. 2019;5:1159–67.

Article  PubMed  PubMed Central  Google Scholar 

Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113:9–21.

Article  PubMed  Google Scholar 

Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens. 2018;31:1165–74.

Article  PubMed  CAS  Google Scholar 

Hu D, Dong R, Zhang Y, Yang Y, Chen Z, Tang Y, et al. Agerelated changes in mineralocorticoid receptors in rat hearts. Mol Med Rep. 2020;22:1859–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Urata T. [Life science: “medicine and man”. Genetic factors and the clinical course in a disease]. Kango Kyoshitsu. 1974;18:34–7.

PubMed  Google Scholar 

Gleissner CA, Galkina E, Nadler JL, Ley K. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech. 2007;4:131–40.

Article  PubMed  PubMed Central  Google Scholar 

Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharm. 2014;18:1–14.

Article  CAS  Google Scholar 

Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharm Res. 2007;55:498–510.

Article  Google Scholar 

Wang Y, Zhang HT, Su XL, Deng XL, Yuan BX, Zhang W, et al. Experimental diabetes mellitus down-regulates large-conductance Ca2+-activated K+ channels in cerebral artery smooth muscle and alters functional conductance. Curr Neurovasc Res. 2010;7:75–84.

Article  PubMed  CAS  Google Scholar 

Deenadayalu V, Puttabyatappa Y, Liu AT, Stallone JN, White RE. Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol. 2012;302:H115–23.

Article  PubMed  CAS  Google Scholar 

Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8:84572–8.

Article  PubMed  PubMed Central  Google Scholar 

Lee HY, Chen HL, Teoh JY, Chen TC, Hao SY, Tsai HY, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021;24:244–52.

Article  PubMed  CAS  Google Scholar 

Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the treatment hierarchy question in network meta-analysis. Am J Epidemiol. 2022;191:930–8.

Article  PubMed  Google Scholar 

Kulkarni AA, Rubin N, Tholkes A, Shah S, Ryan CJ, Lutsey PL, et al. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. ESMO Open. 2021;6:100261.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pazzagli L, Linder M, Zhang M, Vago E, Stang P, Myers D, et al. Methods for time-varying exposure related problems in pharmacoepidemiology: an overview. Pharmacoepidemiol Drug Saf. 2018;27:148–60.

Article  PubMed  Google Scholar 

Morris MJ, Heller G, Bryce AH, Armstrong AJ, Beltran H, Hahn OM, et al. Alliance A031201: a phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37:5008.

Article  Google Scholar 

Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021;22:1541–59.

Article  PubMed  PubMed Central  CAS  Google Scholar